{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:03:02Z","timestamp":1760014982141,"version":"3.37.3"},"reference-count":10,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"funder":[{"name":"Fili\u00e8re Maladies Rares MUCO-CFTR"},{"name":"Soci\u00e9t\u00e9 Fran\u00e7aise de la Mucoviscidose"},{"DOI":"10.13039\/501100006342","name":"Association Vaincre la Mucoviscidose","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2024,2,1]]},"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1183\/13993003.00233-2024","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T09:45:15Z","timestamp":1709199915000},"page":"2400233","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Reply to: Supporting the case for a targeted approach for elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme"],"prefix":"10.1183","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-9828","authenticated-orcid":false,"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"2024102017225341000_63.2.2400233.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02437-2022"},{"key":"2024102017225341000_63.2.2400233.2","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade2216"},{"key":"2024102017225341000_63.2.2400233.3","unstructured":"L'Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM) . D\u00e9cision du 01\/06\/2023 \u2013 Extension de l'indication du cadre de prescription compassionnelle de Kaftrio (ivacaftor, tezacaftor, \u00e9lexacaftor) et Kalydeco (ivacaftor). [Decision of 01\/06\/2023 \u2013 Extension of the indication of the compassionate prescription framework of Kaftrio (ivacaftor, tezacaftor, \u00e9lexacaftor) and Kalydeco (ivacaftor).]. Date last updated: 1 June 2023. https:\/\/ansm.sante.fr\/actualites\/decision-du-01-06-2023-extension-de-lindication-du-cadre-de-prescription-compassionnelle-de-kaftrio-ivacaftor-tezacaftor-elexacaftor-et-kalydeco-ivacaftor"},{"key":"2024102017225341000_63.2.2400233.4","doi-asserted-by":"publisher","DOI":"10.1513\/annalsats.201708-668ps"},{"key":"2024102017225341000_63.2.2400233.5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01192-2015"},{"key":"2024102017225341000_63.2.2400233.6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00110-2023"},{"key":"2024102017225341000_63.2.2400233.7","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcf.2022.10.011","article-title":"Treatment effects of elexacaftor\/tezacaftor\/ivacaftor in people with CF carrying non-F508del mutations","volume":"22","author":"Livnat","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024102017225341000_63.2.2400233.8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01959-2023"},{"key":"2024102017225341000_63.2.2400233.9","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jcf.2023.06.001","article-title":"Clinical and functional efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis carrying the N1303K mutation","volume":"22","author":"Sadras","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024102017225341000_63.2.2400233.10","doi-asserted-by":"crossref","unstructured":"Bihler H , Sivachenko A , Millen L , et al. In vitro modulator responsiveness of 655 CFTR variants found in people with CF. bioRxiv 2023; preprint [https:\/\/doi.org\/10.1101\/2023.07.07.548159]. doi:10.1101\/2023.07.07.548159","DOI":"10.1101\/2023.07.07.548159"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00233-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:18:03Z","timestamp":1740381483000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00233-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,29]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1183\/13993003.00233-2024"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00233-2024","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"type":"print","value":"0903-1936"},{"type":"electronic","value":"1399-3003"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}